Sonographic Visibility of Breast Biopsy Marker Clips Up to 4 Weeks After Placement
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Sonographic Visibility of Breast Biopsy Marker Clips Up to 4 Weeks After Placement|
- Visibility of marker clip after placement in suspicious breast lesions. [ Time Frame: Within 4 weeks of placement ]
Biospecimen Retention: None Retained
|Study Start Date:||May 2007|
|Study Completion Date:||September 2008|
|Primary Completion Date:||September 2008 (Final data collection date for primary outcome measure)|
Many breast cancers and other breast lesions are discovered as a palpable abnormality by patients or their providers during a breast exam. Diagnostic imaging and biopsy of these lesions may reveal high-risk or malignant findings. These palpable lesions can be removed in the operating room by the surgeon using touch as guidance. However, there are many lesions discovered by screening examinations that surgeons cannot palpate. When this occurs, a radiologist will percutaneously place a wire or wires at the site of the breast lesion using sonographic or mammographic guidance. The surgeon then uses the wires as a guide for complete and successful resection of the lesion.
New marker devices have been developed that are sonographically visible. They consist of the standard mammographically visible metallic clip surrounded by a sonographically visible collagen plug. It is hypothesized that radiologists and surgeons can effectively localize the clip with intra-operative ultrasound and then resect the lesion. If so, the pre-operative wire localization procedure could be eliminated. This could improve the patient experience while saving time and money by reducing the number of invasive procedures from 3 (biopsy, wire-localization and operation) to 2 (biopsy and operation).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00548392
|United States, Washington|
|Seattle Cancer Care Alliance|
|Seattle, Washington, United States, 98109-1023|
|Principal Investigator:||Peter R Eby, MD||University of Washington|